for people ages 4 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion:



Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO) often associated with painful, recurrent episodes of soft tissue swelling (flare-ups) that lead to ankyloses of major joints with cumulative and irreversible loss of movement and disability.

Official Title

MOVE TRIAL: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)


One primary objective is to evaluate the efficacy of palovarotene in decreasing new HO in subjects with FOP as assessed by low-dose, whole body computed tomography (WBCT), excluding head, compared to untreated subjects from Clementia's FOP natural history study (Study PVO-1A-001, NHS). The other primary objective is to evaluate the safety of palovarotene in subjects with FOP.

This is a Phase 3, multicenter, open-label study. Eligible subjects will receive a chronic/flare-up dosing regimen of palovarotene for 24 months as follows:

  • Chronic treatment: orally administered 5 mg palovarotene once daily for 24 months.
  • Flare-up treatment: orally administered 20 mg palovarotene once daily for 4 weeks (28 days) followed by orally administered 10 mg palovarotene once daily for 8 weeks (56 days). Flare-up treatment may be extended until the Investigator determines that the flare-up has resolved.

Note that all dosing will be weight-adjusted in skeletally immature subjects (those under the age of 18 years with less than 90% skeletal maturity on hand/ wrist x-rays performed at Screening).


Fibrodysplasia Ossificans Progressiva Interventional study Clinical trial phase 3 Efficacy and safety Heterotopic ossification Flare-up Palovarotene Retinoic acid receptor agonist Retinoic acid receptor gamma agonist Clementia Myositis Ossificans Progressiva Munchmeyer's Disease FOP Myositis Ossificans


For people ages 4 years and up

Key Inclusion Criteria:

  • Written, signed, and dated informed subject/parent consent; and for subjects who are minors, age-appropriate assent (performed according to local regulations).
  • Males or females at least 4 years of age.
  • Clinically diagnosed with FOP, with the R206H ACVR1 mutation.
  • No flare-up symptoms within the past 4 weeks, including at the time of enrollment.
  • Abstinent or using two highly effective forms of birth control.
  • Accessible for treatment and follow-up; able to undergo all study procedures including low-dose WBCT (excluding head).

Key Exclusion Criteria:

  • Weight <10 kg.
  • Concomitant medications that are strong inhibitors or inducers of cytochrome P450(CYP450) 3A4 activity; or kinase inhibitors such as imatinib.
  • Amylase or lipase >2x above the upper limit of normal (ULN) or with a history of chronic pancreatitis.
  • Elevated aspartate aminotransferase or alanine aminotransferase >2.5x ULN.
  • Fasting triglycerides >400 mg/dL with or without therapy.
  • Female subjects who are breastfeeding.
  • Subjects with uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal,endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease.
  • Simultaneous participation in another clinical research study within 4 weeks prior to Screening; or within five half-lives of the investigational agent, whichever is longer.
  • Any reason that, in the opinion of the Investigator, would lead to the inability of the subject and/or family to comply with the protocol.


  • University of California San Francisco, Division of Endocrinology and Metabolism accepting new patients
    San Francisco, California, 94143, United States
  • Toronto General Hospital accepting new patients
    Toronto, Ontario, M5G 2C4, Canada
  • Children's Hospital of Philadelphia accepting new patients
    Philadelphia, Pennsylvania, 19104, United States
  • University of Pennsylvania accepting new patients
    Philadelphia, Pennsylvania, 19104, United States
  • Royal National Orthopaedic Hospital, Brockely Hill accepting new patients
    Stanmore, HA7 4LP, United Kingdom
  • Norrlands Universitetssjukhus accepting new patients
    Umeå, SE-90185, Sweden
  • Groupe Hospitalier Necker Enfants Malades accepting new patients
    Paris, 75015, France
  • Hospital Universitari i Politècnic La Fe, Unidad de Reumatología Pediatrica accepting new patients
    Valencia, Avinguda De Fernando Abril Martorell, Nº 106, 46026, Spain


accepting new patients
Start Date
Completion Date
Clementia Pharmaceuticals Inc.
Website for the International FOP Association
More information about this study
Phase 3
Lead Scientist
Edward Hsiao
Study Type
Last Updated
March 26, 2018